Quantcast

Liquid formulation of pentoxifylline is a poorly tolerated treatment for duchenne dystrophy.

Research paper by Angela A Zimmerman, Paula R PR Clemens, Carolina C Tesi-Rocha, Anne A Connolly, Susan T ST Iannaccone, Nancy N Kuntz, Adrienne A Arrieta, Lauren L Hache, Erik E Henricson, Fengming F Hu, Jill J Mayhew, Diana M DM Escolar

Indexed on: 16 Jun '11Published on: 16 Jun '11Published in: Muscle & Nerve



Abstract

In this study we performed an open-label, pilot study of an orally administered liquid formulation of immediate-release pentoxifylline (PTX) on patients with Duchenne muscular dystrophy (DMD). Treatment efficacy, safety, and tolerability were assessed.The tolerability and safety of PTX and measures of muscle strength and function were evaluated during 12 months of treatment.Seventeen boys with DMD, between 4 and 8 years of age, were enrolled at one of five Cooperative International Neuromuscular Research Group (CINRG) centers. Only 9 were able to complete the 12-month PTX treatment phase; the primary reason for discontinuation was adverse events. Intolerable gastrointestinal side effects were experienced by 65% of participants. Two participants had severe leukopenia that resolved with medication withdrawal.Open-label treatment with a liquid formulation of immediate-release PTX resulted in a high incidence of adverse events in boys with DMD. Poor tolerability of this PTX formulation precluded adequate assessment of efficacy.

More like this: